Jubilant Pharmova
JUBLPHARMA.NS
#4029
Rank
C$3.25 B
Marketcap
$20.24
Share price
-0.94%
Change (1 day)
200.61%
Change (1 year)

P/E ratio for Jubilant Pharmova (JUBLPHARMA.NS)

P/E ratio as of November 2024 (TTM): -421

According to Jubilant Pharmova's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -420.636. At the end of 2022 the company had a P/E ratio of 61.8.

P/E ratio history for Jubilant Pharmova from 2012 to 2023

PE ratio at the end of each year

Year P/E ratio Change
202261.8276.25%
202116.443.61%
202011.4-4.4%
201912.019.39%
201810.0-28.79%
201714.1-18.97%
201617.451.83%
201511.4-3.94%
201411.9-115.21%
2013-78.32207.66%
2012-3.39

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.